The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Rummelt Andreas since 2010.
The trader's CIK number is 1484986.
At the time of the last reporting, Rummelt Andreas was the Director of Alexion Pharmaceuticals, Inc.. (stock ticker symbol ALXN).
Also see all insider trading activities at Alexion Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2014 | ALXN | 0 | $0 | 5,052 | $861,517 | 5,052 | $186,393 |
| 2012 | ALXN | 0 | $0 | 26,443 | $2,520,016 | 9,558 | $226,795 |
| 2011 | ALXN | 0 | $0 | 9,015 | $622,125 | 11,740 | $301,795 |
| 2010 | ALXN | 5,000 | $263,000 | 0 | $0 | 5,875 | $295,272 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-08-25 | ALXN | Option Ex | 5,052 | 36.90 | 186,393 |
| 2014-08-25 | ALXN | Sale | 5,052 | 170.53 | 861,517 |
| 2012-07-27 | ALXN | Sale | 10,000 | 107.00 | 1,070,000 |
| 2012-06-07 | ALXN | Sale | 10,000 | 91.29 | 912,900 |
| 2012-02-21 | ALXN | Option Ex | 2,786 | 49.43 | 137,711 |
| 2012-02-21 | ALXN | Sale | 2,786 | 81.27 | 226,418 |
| 2012-02-23 | ALXN | Option Ex | 3,657 | 24.36 | 89,084 |
| 2012-02-23 | ALXN | Sale | 3,657 | 84.96 | 310,698 |
| 2012-02-03 | ALXN | Option Ex | 3,115 | .00 | 0 |
| 2011-10-24 | ALXN | Option Ex | 9,015 | 33.48 | 301,795 |
| 2011-10-24 | ALXN | Sale | 9,015 | 69.01 | 622,125 |
| 2011-02-02 | ALXN | Option Ex | 2,725 | .00 | 0 |
| 2010-11-23 | ALXN | Option Ex | 1,983 | 53.28 | 105,654 |
| 2010-05-10 | ALXN | Buy | 5,000 | 52.60 | 263,000 |
| 2010-02-23 | ALXN | Option Ex | 3,892 | 48.72 | 189,618 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Rummelt Andreas (Director of Alexion Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.